Tabula Rasa HealthCare (TRHC) Downgraded by Zacks Investment Research

Share on StockTwits

Tabula Rasa HealthCare (NASDAQ:TRHC) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Tabula Rasa HealthCare, Inc. is a provider of patient-specific, data-driven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The company’s cloud-based software applications including EireneRx and MedWise Advisor which provide solutions to payers, providers and other healthcare organizations. Tabula Rasa HealthCare, Inc. is based in NJ, United States. “

Other research analysts also recently issued reports about the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $99.00 price target on shares of Tabula Rasa HealthCare in a report on Monday. Guggenheim assumed coverage on Tabula Rasa HealthCare in a report on Wednesday, April 17th. They set a “neutral” rating and a $58.00 price target on the stock. BidaskClub raised Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a report on Friday, March 22nd. ValuEngine downgraded Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a report on Monday. Finally, Piper Jaffray Companies upped their price target on Tabula Rasa HealthCare from $73.00 to $78.00 and gave the company an “overweight” rating in a report on Thursday, May 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $80.53.

Tabula Rasa HealthCare stock traded up $1.61 during mid-day trading on Wednesday, hitting $48.07. The company had a trading volume of 7,731 shares, compared to its average volume of 361,763. The company has a current ratio of 1.80, a quick ratio of 1.73 and a debt-to-equity ratio of 1.31. Tabula Rasa HealthCare has a 12 month low of $42.29 and a 12 month high of $91.16. The company has a market capitalization of $972.77 million, a price-to-earnings ratio of 141.59 and a beta of 1.51.

Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.14). The firm had revenue of $60.96 million for the quarter, compared to the consensus estimate of $59.24 million. Tabula Rasa HealthCare had a positive return on equity of 4.22% and a negative net margin of 18.15%. On average, equities research analysts predict that Tabula Rasa HealthCare will post -0.63 EPS for the current year.

In related news, CEO Calvin H. Knowlton sold 8,000 shares of the stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $54.50, for a total transaction of $436,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Calvin H. Knowlton sold 8,270 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $53.68, for a total value of $443,933.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 48,270 shares of company stock valued at $2,645,294. Company insiders own 14.00% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in Tabula Rasa HealthCare by 1.8% during the first quarter. BlackRock Inc. now owns 2,647,485 shares of the company’s stock valued at $149,370,000 after buying an additional 46,601 shares during the last quarter. Vanguard Group Inc lifted its stake in shares of Tabula Rasa HealthCare by 6.9% in the 3rd quarter. Vanguard Group Inc now owns 967,769 shares of the company’s stock valued at $78,573,000 after purchasing an additional 62,267 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Tabula Rasa HealthCare by 6.9% in the 3rd quarter. Vanguard Group Inc. now owns 967,769 shares of the company’s stock valued at $78,573,000 after purchasing an additional 62,267 shares during the last quarter. Jennison Associates LLC lifted its stake in shares of Tabula Rasa HealthCare by 17.2% in the 1st quarter. Jennison Associates LLC now owns 885,611 shares of the company’s stock valued at $49,966,000 after purchasing an additional 130,137 shares during the last quarter. Finally, M&T Bank Corp bought a new stake in shares of Tabula Rasa HealthCare in the 4th quarter valued at approximately $33,749,000. 76.85% of the stock is owned by institutional investors.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Further Reading: What is Blockchain?

Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Tabula Rasa HealthCare  Downgraded by Zacks Investment Research
Tabula Rasa HealthCare Downgraded by Zacks Investment Research
Puregold Token  Reaches Market Capitalization of $156,924.00
Puregold Token Reaches Market Capitalization of $156,924.00
Head-To-Head Comparison: Atara Biotherapeutics  and Applied Genetic Technologies
Head-To-Head Comparison: Atara Biotherapeutics and Applied Genetic Technologies
Bank of Nova Scotia  Price Target Cut to C$74.00
Bank of Nova Scotia Price Target Cut to C$74.00
CIBC Lowers Tidewater Midstream & Infrastructure  Price Target to C$2.05
CIBC Lowers Tidewater Midstream & Infrastructure Price Target to C$2.05
Control4 Corp  Director Phil Molyneux Sells 23,374 Shares
Control4 Corp Director Phil Molyneux Sells 23,374 Shares


© 2006-2019 Ticker Report